Petitions Denied For ‘Pharmacist Category’ Nonprescription Viagra, Lipitor, Chantix
This article was originally published in The Tan Sheet
The petitioner offers no evidence to support establishing a “Pharmacists Category of Drugs Behind the Counter” status for nonprescription sales with continued Rx distribution of Viagra, Lipitor, Narcan and Chantix, CDER Director Woodcock says in rejecting a petition on each drug.
You may also be interested in...
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.